Didanosine-d2 (Synonyms: ddl-d2, 2′,3′-Dideoxyinosine-d2) |
カタログ番号GC49022
One-Click Copy Product Info
|
ジダノシンの定量化のための内部標準
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 69655-05-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Didanosine-d2 is intended for use as an internal standard for the quantification of didanosine by GC- or LC-MS. Didanosine is an antiviral nucleoside analog and an inhibitor of reverse transcriptase.1 It undergoes cellular amination and phosphorylation to its active triphosphate form, 2’,3’-dideoxyadenosine 5’-triphosphate . Didanosine inhibits human T cell leukemia virus type 1 (HTLV-1) reverse transcriptase activity (IC50 = 30 nM).2 It inhibits the replication of HIV-1 clinical isolates containing various mutations in the gene encoding reverse transcriptase, pol, in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 0.3-11.1 μM).3 Didanosine inhibits proliferation and differentiation of primary human skeletal muscle cells (IC50s = 1 and 0.1 mM, respectively), as well as decreases the activities of mitochondrial complex IV, also known as cytochrome c oxidase, and mitochondrial complex II, also known as succinate dehydrogenase, in the same cells when used at a concentration of 1 mM.4 In vivo, didanosine protects mice from HIV infection (EC50 = 13.7 mg/kg).5 Formulations containing didanosine have been used in the treatment of HIV-1 infections.
1.Perry, C.M., and Noble, S.Didanosine: An updated review of its use in HIV infectionDrugs58(6)1099-1135(1999) 2.Anantharaman, V., and Moen, L.K.Effects of nucleoside analogs on native and site-directed mutants of HTLV type 1 reverse transcriptaseBioorg. Chem.28(5)293-305(2000) 3.Eron, J.J., Chow, Y.-K., Caliendo, A.M., et al.pol Mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoAntimicrob. Agents Chemother.37(7)1480-1487(1993) 4.Benbrik, E., Chariot, P., Bonavaud, S., et al.Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cellsJ. Neurol. Sci.149(1)19-25(1997) 5.Kaneshima, H., Shih, C.C., Namikawa, R., et al.Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouseProc. Natl. Acad. Sci. USA88(10)4523-4527(1991)
| Cas No. | 69655-05-6 | SDF | |
| 同義語 | ddl-d2, 2′,3′-Dideoxyinosine-d2 | ||
| Canonical SMILES | OC[C@@H]1CC[C@H](N2C([2H])N=C3C2N=C([2H])NC3=O)O1 | ||
| Formula | C10H12D2N4O3 | M.Wt | 240.3 |
| 溶解度 | DMSO : 62.5 mg/mL (264.57 mM; Need ultrasonic) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1615 mL | 20.8073 mL | 41.6146 mL |
| 5 mM | 832.3 μL | 4.1615 mL | 8.3229 mL |
| 10 mM | 416.1 μL | 2.0807 mL | 4.1615 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)